Spot­light Ther­a­peu­tics, a start­up with a bold vi­sion for de­liv­er­ing CRISPR ther­a­pies in­to the body with­out the ...

A month af­ter Bio­gen sig­naled plans to shift its at­ten­tion to “ ex­ter­nal op­por­tu­ni­ties ,” it de­liv­ered on that ...

The federal government said it 'ran afoul of no statute' when it announced a 15% cap on indirect cost reimbursements for NIH ...

Arcus Biosciences presented new Phase 1/1b data for a kidney cancer program over the weekend and picked a dose to move ...

Subsense, a startup building noninvasive technology to communicate with the brain, is launching with $17 million in funding.

Siegfried’s stock dipped by 6% on the Swiss stock exchange Tuesday after reporting a lower-than-expected sales forecast for ...

Hik­ma Phar­ma­ceu­ti­cals is ask­ing the US Supreme Court to re­view a gener­ic drug la­bel­ing rul­ing that it says will ...

A judge in Singapore ordered the freezing of KBP Biosciences’ assets while Novo Nordisk pursues $830 million in damages over claims that it was deceived in a 2023 licensing deal.

Septerna halts Phase 1 trial of SEP-786 for hypoparathyroidism due to safety concerns, FDA approves Sanofi's Merilog insulin biosimilar, plus updates from Basilea and TME Pharma ...

The former head of the FDA on Tuesday criticized the Trump administration’s efforts to lay off recently hired employees who review the safety of medical devices and other products.

Trump administration establishes Make America Healthy Again commission, fires HHS workers including FDA/CMS staff. FDA AI division hit by cuts.

FDA approves Ono Pharmaceutical's Romvimza for TGCT, meaning it will compete with Daiichi Sankyo's Turalio. Drug shows better safety profile and twice-weekly dosing vs twice-daily Turalio.